Home

The firm

Team

Portfolio

Investors

GOVERNANCE

Connect

  • Loading stock data...

Nordicus Partners Corp. (NORD)

Investor overview

Nordicus Partners is the only publicly traded U.S. business accelerator and holding company focused exclusively on empowering Nordic life sciences companies to succeed in the U.S. market. By combining Nordic scientific innovation with U.S. operational expertise, Nordicus targets transformative, scalable opportunities in high-growth life sciences with unmet medical needs. Current portfolio companies include Orocidin who is developing treatments against aggressive periodontal disease, and Bio-Convert who is focused on preventing oral leukoplakia, a potentially cancerous lesion in the mouth.

Latest News

2
September, 2026

NORDICUS PARTNERS CORPORATION APPOINTS ELIZABETH ADDONIZIO TO ITS BOARD OF DIRECTORS

Read More
15
June, 2026

NORDICUS PARTNERS CORPORATION CORPORATE UPDATE

Read More
Load more

Regulatory Filings

FILING DATE:

July 14, 2026

Annual Report (10-K)

Read More

FILING DATE:

February 13, 2026

Quarterly Report (10-Q)

Read More

In The Press

Navigating Corporate Finance in the Life Sciences Sector

Read Full Article At Best Stocks
20
Feb, 2024
Load more

Contact

Media Inquiries:

Ulveman & Børsting
Copenhagen, Denmark
Tel: +45 31 906 900
Mail: Kontakt@ulvemanborsting.com

Transfer Agent:

Transfer Online, Inc.
512 SE Salmon St.
Portland, OR 97214
Tel:+1 503-227-2950
Mail: info@transferonline.com

Investor

FAQs

US Office

Nordicus Partners Corp. resides at 280 S. Beverly Drive, Suite 505, Beverly Hills, CA 90212.

DK Office

C/O NP Bioinnovation A/S
Address: Vandtårnsvej 62A, 1. E, DK-2860 Søborg, Denmark.

Nordicus Partners Corp. was founded in 1993 under its original Company name; Cardiotech International, Inc.

Nordicus Partners Corporation is a U.S. publicly traded business accelerator and holding company focused exclusively on empowering Nordic life sciences companies to succeed in the U.S. market.

Nordicus Partners Corp. went public in 1993 under its original name Cardiotech International, Inc. Mitsubishi Chemical Performance Polymers acquired AdvanSource Biomaterials Corporation (formerly Cardiotech International, Inc.) on January 31, 2020, which led to the company becoming a shell company with no operational activity. Conversely, the company changed its name to EKIMAS Corporation and later became Nordicus Partners Corp. as we know it today.

Nordicus Partners Corp. is currently listed on the OTCQB Market, with the ticker symbol "NORD".

Nordicus Partners Corp. fiscal year ends on March 31.

Please contact a stockbroker, bank, or other institution that offers brokerage services to buy or sell Nordicus Partners Corp. common stock.

Please contact our Investor Relations department, using our contact form.

Nordicus Partners Corp. transfer agent is Transfer Online, Inc. They can be reached at the following addresses:

Website: https://transferonline.com/

E-mail inquiries: info@transferonline.com

Transfer Online, Inc.
512 SE Salmon St.
Portland, OR 97214

Please contact our transfer agent, Transfer Online, Inc., to make changes.

Within 45 days after our quarter ends, a 10-Q will be filed with the SEC and within 90 days after our fiscal year end, a 10-K will be filed with the SEC.

Nordicus Partners Corp. does not currently pay dividends.

Nordicus Partners Corp. independent registered public accounting firms is Fruci & Associates II, PLLC

Our legal counsel is Lucosky Brookman LLP

All SEC filings can be accessed directly from the SEC, here.

Nordicus Partners Corp. Investor Relations department can provide information regarding financial performance and business strategy that is already made public.
You can contact Investor Relations through our contact page here.

Kim Mücke

Member, Board of Directors

Kim T. Mücke is a Danish state authorized public accountant (authorization deposited in 2025). He was partner with Deloitte (Denmark) in the period 2002 to 2022 where he – among others – served as signing partner for various listed companies including companies that underwent IPO processes. In the years 2023-2024, Mr. Mücke was Head of Corporate Clients for BDO (Denmark). From 1 January 2025, Mr. Mücke has started as independent advisor,specialized in financial reporting, risk management and corporate governance. Mr. Mücke has a master’s degree in Auditing and Accounting from the Copenhagen Business School.

Elizabeth Addonizio

Member, Board of Directors

Elizabeth Addonizio is an experienced finance professional with twenty-five years of business and leadership experience. She is the founder of Fair Winds Capital LLC, AMN LLC, and GEDI LLC, through which she has spent the past decade investing, along with families and entrepreneurs, in U.S.-based, sector-agnostic, early-stage venture investments that prioritize impact and environmental, social, and good governance (ESG) principles by investing in companies’ Pre-seed to C-round capital raises. She has also served as a fractional CFO for many companies in diverse sectors.

Prior to her venture investing and CFO work, from 2012 to 2016, Ms. Addonizio was a founding managing director and investment professional at Cranemere, an international investment holding company and private equity firm structured to invest with a commitment to sustainability and ESG principles, along with other families, in middle market private companies (~$200mm-$500mm in enterprise value). While at Cranemere she sourced and evaluated dozens of investment opportunities, serving on the firm’s Investment Committee, and overseeing due diligence, financing, and other acquisition-related activities. Prior to joining Cranemere, from 2006 to 2012, Ms. Addonizio worked at Morgan Stanley in the Investment Banking and Corporate M&A and Strategy Divisions, advising on over $25 billion of mergers and acquisitions, leveraged finance, and equity transactions.

In addition to her work in finance, since 2004, Ms. Addonizio has served as an intelligence officer in the U.S. Navy Reserve. Currently, she is the board-selected Commanding Officer of the 30-member Navy Reserve Office of Naval Intelligence (ONI) Kennedy Maritime Analysis Center Unit in St. Louis, MO. Previously, she was Executive Officer of 110+-person Navy Reserve Joint Intelligence Operations Center Europe (JIOCEUR) Analytic Center Molesworth 0366 (located at Joint Reserve Intelligence Support Element Sheridan, Fort Sheridan, IL). Prior to this position, she served as the board-selected Executive Officer of 75-person ONI Navy Reserve Nimitz Unit at Fort Dix, NJ. She was also the Officer in Charge (OIC) of a twenty-eight-person Naval Criminal Investigative Service (NCIS) Unit based in New London, CT. Board-selected to hold this position, she was one of only three to have command of a unit at her rank in the Navy Reserve Intelligence Community, the first woman to ever serve in this NCIS unit, and by extension, the unit’s first female OIC. During her twenty years in the U.S. Navy, she has led numerous teams in support of JIOCEUR, ONI, NCIS, and the Defense Intelligence Agency (DIA). She also served 20 months of active military duty as an analyst on the personal staff of the Commander of U.S. Central Command, General David Petraeus.

Earlier in her career, Ms. Addonizio was elected to serve two terms as the 9th Ward Alderwoman in New Haven, Connecticut, serving as the Vice Chair of the Finance Committee with legislative oversight of the city’s $450 million annual budget. As a Henry Luce Scholar in China, she taught economics at Peking University and worked on China’s accession to the World Trade Organization at the World Bank Resident Mission. She has also worked in the U.S. National Security Council and in the Office of the U.S. Trade Representative. She holds a Ph.D. from Yale University, a M.P.A. from Princeton University, a B.A. from Bucknell University, and was a Fulbright Scholar in El Salvador. Ms. Addonizio is currently a member of the Association for Corporate Growth and the Alliance of Merger and Acquisitions Advisers. She is also a Council on Foreign Relations Life Member, a NationSwell Council Member, a Truman National Security Project Fellow, and a Yale World Fellow.